Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine reversal of rocuronium for recurrent laryngeal nerve monitoring during thyroid cancer surgery
ChiCTR1800015797Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of neostigmine and rocuronium in thyroid cancer (5 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Train-of-four ratio and Recurrent laryngeal nerve electrical signal. Planned start May 2018; status: not yet recruiting.
02
Drugs
neostigminerocuronium
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on ChiCTR1800015797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015797.